Health
N.I.H. Bans New Funding From U.S. Scientists to Partners Abroad
The National Institutes of Health will no longer allow American scientists to direct its funding to research partners overseas, casting doubt on the future of studies on subjects including malaria and childhood cancer.
Dr. Jay Bhattacharya, the new director of the N.I.H., announced the policy on Thursday, the same day Dr. Matthew J. Memoli, the principal deputy director, blasted these so-called subawards in an email obtained by The New York Times.
“If you can’t clearly justify why you are doing something overseas, as in it can’t possibly be done anywhere else and it benefits the American people,” Dr. Memoli wrote, “then the project should be closed down.”
The new restrictions, which will apply to domestic subawards as well in the future, come amid deep reductions in N.I.H. funding and the freezing of federal grants at many top universities, along with executive orders seeking to reshape the nation’s scientific agenda.
On Monday, President Trump signed an executive order restricting a type of experimentation that can make pathogens more dangerous to humans, and ending support for the so-called gain-of-function research in countries like China.
Researchers funded by N.I.H. grants have historically used subawards to facilitate international collaborations, which are essential for studying conditions like childhood cancer or illnesses like malaria and tuberculosis that are not prevalent in the United States.
The subawards are legal and financial agreements made between the grant recipients and their overseas partners. The practice is used throughout the federal government and is not unique to the N.I.H.
But it has come under fire in recent years because of lax reporting and tracking of funds. After a critical report by the Government Accountability Office in 2023, the N.I.H. put stricter monitoring requirements in place.
Advocates for scientific and medical research said that as science has become more complex, collaborative initiatives that draw participants and scientists from around the world have become more critical.
“Competitive science requires a team approach,” said Dr. E. Anders Kolb, chief executive of the Leukemia & Lymphoma Society. “There’s no one lab or institution or investigator that has all of the tools necessary to solve the very complex questions that we’re asking.”
Many of these studies require a large number of subjects. For example, as scientists are able to define types of childhood cancers more precisely, Dr. Kolb said, “you get into increasingly smaller and smaller subsets of disease.”
“So if you want to run a clinical trial of a new therapy that may benefit those children, it could take decades to complete a trial if you only enroll children in the U.S.,” he added. “When we collaborate with our international partners, we can finish these trials much more quickly and get the therapies to children as soon as possible.”
In announcing the new directive, Dr. Bhattacharya cited recent Government Accountability Office reports that have been critical of funding given to international universities and laboratories, as well as businesses.
The issues highlighted by the G.A.O. reports “can lead to a breakdown in trust and potentially the security of the U.S. biomedical research enterprise,” Dr. Bhattacharya added.
N.I.H. spending on these international groups is difficult to track, one of the faults noted by the G.A.O. The journal Nature, which first reported the new policy, estimated the total at approximately $500 million a year.
Dr. Monica Gandhi, a professor of medicine at the University of California, San Francisco, has N.I.H. funding to study H.I.V. prevention and treatment in Kenya and South Africa, work that will be affected by the new policy.
Researchers like her must provide detailed information about international subawards when they apply for their grants, she said, including justifications for using a foreign entity and for each aspect of the budget.
International partners must now provide access to their lab notebooks, data and other documentation at least once a year, Dr. Gandhi noted. All of the expenditures are tracked on a system called the Foreign Award and Component Tracking System, or FACTS, she said.
“It’s very rigorous, as it should be when you’re using taxpayer dollars,” Dr. Gandhi said.
“Every year when you put in your progress report, you account for every penny that was spent at the foreign site — where it went, how much to lab tests, how much was paid investigators, every aspect.”
It wasn’t immediately clear how the new policy would be implemented. The N.I.H. did not respond to requests for additional information.
The N.I.H. will not retroactively halt foreign subawards already in place “at this time” and will continue to make awards directly to international groups, the agency’s statement said.
But the new policy will forbid new competing awards and noncompeting awards to be reissued if they propose subawards to foreign institutions.
“If a project is no longer viable without the foreign subawards, N.I.H. will work with the recipient to negotiate a bilateral termination of the project,” the statement said.
The new policy appeared to be somewhat less draconian than the summation put forth by Dr. Memoli in his internal email, which threatened immediate action to shut down or pause international sites.
“Subawards to foreign sites can’t continue,” he wrote. “This has been horribly mismanaged for years and it has been completely irresponsible. We must take immediate action. If a study has a foreign site we need to start closing it down or finding a different way to fund it that can be tracked properly.”
G.A.O. reports that had criticized various federal departments for lax reporting had called for improving oversight. But the office did not recommend terminating such funding altogether.
In 2023, a G.A.O. report reviewed $2 million in direct awards and subawards, most of it from the N.I.H., given to three Chinese research institutions, including the Wuhan Institute of Virology, between 2014 and 2021.
The virology institute received subawards from the University of California, Irvine, and from the nonprofit group EcoHealth Alliance. The alliance’s work with Chinese scientists led former President Joseph R. Biden Jr. to suspend its funding last year. The Trump administration recently changed the government portal for Covid information with a website suggesting that the new virus originated in a lab in Wuhan.
The G.A.O. report said that N.I.H. oversight didn’t always ensure that the foreign institutions complied with terms and conditions, including biosafety requirements.
One reason expenditures were hard to track was because of a federal government policy that required reporting subawards only of $30,000 or more, another G.A.O. report said.
That report examined some $48 million in N.I.H. and State Department funding that went to Chinese businesses and research institutions between 2017 and 2021, including one project to study diseases that are transmitted by insects, like malaria.
It found that “the full extent of these subawards is unknown,” and that data was incomplete and sometimes inaccurate, because so many expenditures were exempt from reporting.
Apoorva Mandavilli contributed reporting.
NEWYou can now listen to Fox News articles!
A new study suggests that middle-aged men may be more vulnerable to faster biological aging, potentially linked to exposure to “forever chemicals.”
The research, published in the journal Frontiers in Aging, examined how perfluoroalkyl and polyfluoroalkyl substances, more commonly known as PFAS, could impact aging at the cellular level.
PFAS are synthetic chemicals commonly used in nonstick cookware, food packaging, water-resistant fabrics and other consumer products, the study noted.
Their chemical structure makes them highly resistant to breaking down, allowing them to accumulate in water, soil and the human body.
Chinese researchers analyzed blood samples from 326 adults enrolled in the U.S. National Health and Nutrition Examination Survey between 1999 and 2000.
A new study suggests that middle-aged men could face accelerated biological aging at the cellular level due to exposure to PFAS. (iStock)
The researchers measured levels of 11 PFAS compounds in participants’ blood and used DNA-based “epigenetic clocks” — tools that analyze chemical changes to DNA to estimate biological age — to determine how quickly their bodies were aging at the cellular level, the study stated.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Two compounds, perfluorononanoic acid (PFNA) and perfluorooctanesulfonamide (PFOSA), were detected in 95% of participants.
Higher concentrations of those chemicals were associated with faster biological aging in men of certain age groups, but not in women.
“People should not panic.”
The compounds most strongly linked to accelerated aging were not the PFAS chemicals that typically receive the most public attention, the researchers noted.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“The associations were strongest in adults aged 50 to 64, particularly in men,” Dr. Xiangwei Li, professor at Shanghai Jiao Tong University School of Medicine and the study’s corresponding author, told Fox News Digital.
“While this does not establish that PFAS cause aging, it suggests that these widely present ‘forever chemicals’ may be linked to molecular changes related to long-term health and aging.”
The study found that two of the compounds were detected in 95% of participants, and higher levels were linked to faster biological aging in men ages 50–64. (iStock)
Midlife may represent a more sensitive biological period, when the body becomes more vulnerable to age-related stressors, according to the researchers.
Lifestyle factors, such as smoking, may influence biological aging markers, potentially increasing vulnerability to environmental pollutants.
While Li said “people should not panic,” she does recommend looking for reasonable ways to reduce exposure.
That might mean checking local drinking water reports, using certified water filters designed to reduce PFAS, and limiting the use of stain- or grease-resistant products when alternatives are available.
CLICK HERE FOR MORE LIFESTYLE STORIES
Meaningful reductions in PFAS exposure will likely depend on broader regulatory action and environmental cleanup efforts, Li added.
The researchers noted that midlife could be a particularly sensitive stage, when the body is more susceptible to stressors associated with aging. (iStock)
Study limitations
The researchers outlined several important limitations of the research, including that the findings show an association, but do not prove that PFAS directly causes accelerated aging.
“The study is cross-sectional, meaning exposure and aging markers were measured at the same time, so we cannot determine causality,” Li told Fox News Digital.
The study was also relatively small, limited to 326 adults age 50 or older, which means the findings may not apply to younger people or broader populations.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Researchers measured PFAS levels using data collected between 1999 and 2000, and today’s exposure patterns may differ.
Li added that while PFAS is known to persist in the environment and the body, these results should be validated through larger, more recent studies that follow participants over time.
Related Article
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
A drug that has long been used to treat seizures has shown promise as a potential means of Alzheimer’s prevention, a new study suggests.
The anti-seizure medication, levetiracetam, was first approved by the FDA in November 1999 under the brand name Keppra as a therapy for partial-onset seizures in adults. The approval has since expanded to include children and other types of seizures.
Northwestern University researchers recently found that levetiracetam prevented the formation of toxic amyloid beta peptides, which are small protein fragments in the brain that are commonly seen in Alzheimer’s patients.
The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons, according to the study findings, which were published in Science Translational Medicine.
The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease.
The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons. (iStock)
“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid‑beta 42 peptides and amyloid plaques,” said corresponding author Jeffrey Savas, associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine, in a press release.
“Our new results uncovered new biology while also opening doors for new drug targets.”
HIDDEN BRAIN CONDITION MAY QUADRUPLE DEMENTIA RISK IN OLDER ADULTS, STUDY SUGGESTS
The brain is better able to avoid the pathway that produces toxic amyloid‑beta 42 proteins in younger years, but the aging process gradually weakens that ability, Savas noted.
“This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he said.
The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease. (iStock)
That then leads to tau (“tangles”) — abnormal clumps of protein inside brain neurons — which can kill brain cells, trigger neuroinflammation and lead to dementia.
In order for levetiracetam to function as an Alzheimer’s blocker, high-risk patients would have to start taking it “very, very early,” Savas said — up to 20 years before elevated amyloid-beta 42 levels would be detected.
CLICK HERE FOR MORE HEALTH STORIES
“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death,” the researcher noted.
The researchers also did a deep dive into previous human clinical data to determine whether Alzheimer’s patients who were taking the anti-seizure drug had slower cognitive decline. They reported that the patients in that category had a “significant delay” in the span from cognitive decline to death compared to those not taking the drug.
“This analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” the researcher said. (iStock)
“Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas said.
Looking ahead, the research team aims to find people who have genetic forms of Alzheimer’s to participate in testing, Savas said.
Limitations and caveats
The study had several limitations, including that it relied on animal models and cultured cells, with no human trials conducted.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Because the study was observational in nature, it can’t prove that the medication caused the prevention of the toxic brain proteins, the researchers acknowledged.
Savas noted that levetiracetam “is not perfect,” cautioning that it breaks down in the body very quickly.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The team is currently working to create a “better version” that would last longer in the body and “better target the mechanism that prevents the production of the plaques.”
“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death.”
The medication’s common documented side effects include drowsiness, weakness, dizziness, irritability, headache, loss of appetite and nasal congestion.
It has also been linked to potential mood and behavior changes, including anxiety, depression, agitation and aggression, according to the prescribing information. In rare cases, it could lead to severe allergic reactions, skin reactions, blood disorders and suicidal ideation.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Funding for the study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund.
Fox News Digital reached out to the drug manufacturer and the researchers for comment.
Related Article
Maxime Giroux – ‘In Cold Light’ movie review
The sea is higher than we thought and millions more are at risk, study finds
Video: U.S. ‘Accelerating’ Military Assault in Iran, Hegseth Says
On the brink of death, a woman is saved by a stranger and his family
MacBook Neo versus an old MacBook Air: good luck
Florida High School Football Rankings: Top 25 teams – Oct. 21
Cleary's 21 help Le Moyne down Central Connecticut State 69-64 in OT
How old is Bo Nix? What to know about Oregon quarterback ahead of 2024 NFL Draft
99th annual Pony Swim held in Virginia
Indiana Members Credit Union announced as new anchor tenant at Bottleworks District
US submarine sinks Iranian warship by torpedo in a first since World War II
Which oil and gas facilities in the Gulf have been attacked?
Mojtaba Khamenei, son of former supreme leader, tipped to become Iran’s next head of state
Video: Senators Question Kristi Noem on ICE Immigration Tactics
Combustible Republican Senate primary in Texas heading into overtime
-
World7 days agoExclusive: DeepSeek withholds latest AI model from US chipmakers including Nvidia, sources say
-
Massachusetts7 days agoMother and daughter injured in Taunton house explosion
-
Denver, CO7 days ago10 acres charred, 5 injured in Thornton grass fire, evacuation orders lifted
-
Louisiana1 week agoWildfire near Gum Swamp Road in Livingston Parish now under control; more than 200 acres burned
-
Florida3 days agoFlorida man rescued after being stuck in shoulder-deep mud for days
-
Oregon5 days ago2026 OSAA Oregon Wrestling State Championship Results And Brackets – FloWrestling
-
Maryland3 days agoAM showers Sunday in Maryland
-
Wisconsin2 days agoSetting sail on iceboats across a frozen lake in Wisconsin